Incretin mimetics administered by auto-injectors or pens enable significant weight reduction and offer an important means of ...

Eli Lilly & Co.'s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

With a market cap of $717 billion, Eli Lilly (LLY) is one of the world’s largest pharmaceutical companies. Lilly is ...

Eli Lilly's (LLY.N) new experimental pill has seen success in its Phase 3 clinical trial. The new pill, orforglipron could ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming ...